We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 12,026.00 | 12,006.00 | 12,012.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.26 | 186.15B |
TIDMAZN
RNS Number : 5981S
AstraZeneca PLC
12 March 2019
12 March 2019 12:00 GMT
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
AstraZeneca PLC (the Company) announces that, on 8 March 2019, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.
PDMR Ordinary Shares Ordinary Shares Award price per granted under granted under Ordinary Share the AZDBP the AZPSP Pascal Soriot 9,849 102,475 GBP62.87 ---------------- ---------------- ---------------- Marc Dunoyer 4,874 48,690 GBP62.87 ---------------- ---------------- ----------------
The AZDBP award represents the portion of each PDMR's annual bonus for 2018 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.
The AZPSP award is subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year performance period (1 January 2019 to 31 December 2021). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.
Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2018, which is available on the Company's website at www.astrazeneca.com/annualreport2018.
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Pascal Soriot ---------------------------- ------------------------------------- 2 Reason for the notification ------------------------------------------------------------------- a) Position/status Chief Executive Officer ---------------------------- ------------------------------------- b) Initial notification Initial notification /Amendment ---------------------------- ------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------- a) Name AstraZeneca PLC ---------------------------- ------------------------------------- b) LEI PY6ZZQWO2IZFZC3IOL08 ---------------------------- ------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------- a) Description of the Ordinary Shares of US$0.25 each in financial instrument, AstraZeneca PLC type of instrument Identification code GB0009895292 ---------------------------- ------------------------------------- b) Nature of the transaction Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan ---------------------------- ------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) GBP62.87 112,324 ---------- ---------------------------- ------------------------------------- d) Aggregated information Not applicable - single transaction - Aggregated volume - Price ---------------------------- ------------------------------------- e) Date of the transaction 8 March 2019 ---------------------------- ------------------------------------- f) Place of the transaction Outside a trading venue ---------------------------- ------------------------------------- 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Marc Dunoyer ---------------------------- ------------------------------------- 2 Reason for the notification ------------------------------------------------------------------- a) Position/status Chief Financial Officer ---------------------------- ------------------------------------- b) Initial notification Initial notification /Amendment ---------------------------- ------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------- a) Name AstraZeneca PLC ---------------------------- ------------------------------------- b) LEI PY6ZZQWO2IZFZC3IOL08 ---------------------------- ------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------- a) Description of the Ordinary Shares of US$0.25 each in financial instrument, AstraZeneca PLC type of instrument Identification code GB0009895292 ---------------------------- ------------------------------------- b) Nature of the transaction Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan ---------------------------- ------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) GBP62.87 53,564 ---------- ---------------------------- ------------------------------------- d) Aggregated information Not applicable - single transaction - Aggregated volume - Price ---------------------------- ------------------------------------- e) Date of the transaction 8 March 2019 ---------------------------- ------------------------------------- f) Place of the transaction Outside a trading venue ---------------------------- -------------------------------------
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations Gonzalo Viña UK/Global +44 203 749 5916 Rob Skelding UK/Global +44 203 749 5821 Matt Kent UK/Global +44 203 749 5906 Jennifer Hursit UK/Global +44 203 749 5762 Christina Malmberg Hägerstrand Sweden +46 8 552 53 106 Michele Meixell US +1 302 885 2677 Investor Relations Thomas Kudsk Larsen +44 203 749 5712 Henry Wheeler Oncology +44 203 749 5797 Christer Gruvris BioPharma - Cardiovascular; Metabolism +44 203 749 5711 Nick Stone BioPharma - Respiratory; Renal +44 203 749 5716 Josie Afolabi Other +44 203 749 5631 Craig Marks Finance; Fixed Income +44 7881 615 764 Jennifer Kretzmann Retail Investors; Corporate Access +44 203 749 5824 US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHUUARRKNAOAAR
(END) Dow Jones Newswires
March 12, 2019 08:00 ET (12:00 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions